Literature DB >> 28669281

The global cancer burden and human development: A review.

Miranda M Fidler1, Freddie Bray1, Isabelle Soerjomataram1.   

Abstract

AIMS: This review examines the links between human development and cancer overall and for specific types of cancer, as well as cancer-related risk-factors and outcomes, such as disability and life expectancy.
METHODS: To assess human development, the Human Development Index was utilized continuously and according to four levels (low, medium, high, very high), where the low and very high categories include the least and most developed countries, respectively. All studies that assessed aspects of the global cancer burden using this measure were reviewed.
RESULTS: Although the present cancer incidence burden is greater in higher Human Development Index countries, a greater proportion of the global mortality burden is observed in less developed countries, with a higher mean fatality rate in the latter countries. Further, the future cancer burden is expected to disproportionally affect less developed regions; in particular, it has been estimated that low and medium Human Development Index countries will experience a 100% and 81% increase in cancer incidence from 2008 to 2030, respectively. Disparities were also observed in risk factors and average health outcomes, such as a greater number of years of life lost prematurely and fewer cancer-related gains in life expectancy observed in lower versus higher Human Development Index settings.
CONCLUSIONS: From a global perspective, there remain clear disparities in the cancer burden according to national Human Development Index scores. International efforts are needed to aid countries in social and economic transition in order to efficiently plan, implement and evaluate cancer control initiatives as a means to reduce the widening gap in cancer occurrence and survival worldwide.

Entities:  

Keywords:  Cancer; global; human development; incidence; inequalities; review; socioeconomic

Mesh:

Year:  2017        PMID: 28669281     DOI: 10.1177/1403494817715400

Source DB:  PubMed          Journal:  Scand J Public Health        ISSN: 1403-4948            Impact factor:   3.021


  68 in total

1.  Diffusion-weighted breast imaging.

Authors:  K Deike-Hofmann; T Kuder; F König; D Paech; C Dreher; S Delorme; H-P Schlemmer; S Bickelhaupt
Journal:  Radiologe       Date:  2018-11       Impact factor: 0.635

2.  Incidence and mortality of cancer in the Volta Region of Ghana.

Authors:  Samuel M Adadey; Sylvester Languon; Richmond Ayee; Darius Nk Quansah; Osbourne Quaye
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-04

Review 3.  Acute kidney injury in cancer patients.

Authors:  Shuiying Liu; Jinyuan Zhao; Feng Wang
Journal:  Clin Exp Nephrol       Date:  2021-09-09       Impact factor: 2.801

4.  EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).

Authors:  Alejandro Ruiz-Patiño; Christian David Castro; Luisa María Ricaurte; Andrés F Cardona; Leonardo Rojas; Zyanya Lucia Zatarain-Barrón; Beatriz Wills; Noemí Reguart; Hernán Carranza; Carlos Vargas; Jorge Otero; Luis Corrales; Claudio Martín; Pilar Archila; July Rodriguez; Jenny Avila; Melissa Bravo; Luis Eduardo Pino; Rafael Rosell; Oscar Arrieta
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

5.  Establishment and characterization of McA-RH7777 cells using virus-mediated stable overexpression of enhanced green fluorescent protein.

Authors:  Wei Zhang; Sheng Qian; Guowei Yang; Liang Zhu; Bo Zhou; Xudong Qu; Zhiping Yan; Rong Liu; Jianhua Wang
Journal:  Exp Ther Med       Date:  2018-08-07       Impact factor: 2.447

6.  TMED3 promotes the progression and development of lung squamous cell carcinoma by regulating EZR.

Authors:  An Xie; Xinping Xu; Peng Kuang; Ling Zhang; Feng Yu
Journal:  Cell Death Dis       Date:  2021-08-24       Impact factor: 8.469

Review 7.  Targeting the mu-Opioid Receptor for Cancer Treatment.

Authors:  Hao Zhang; Di Zhou; Jiahui Gu; Mengdi Qu; Kefang Guo; Wankun Chen; Changhong Miao
Journal:  Curr Oncol Rep       Date:  2021-08-03       Impact factor: 5.075

8.  Management of Head and Neck Cancers With or Without Comorbid HIV Infection in Botswana.

Authors:  Gwendolyn J McGinnis; Matthew S Ning; Memory Bvochora-Nsingo; Sebathu Chiyapo; Dawn Balang; Tlotlo Ralefala; Alexander Lin; Nicola M Zetola; Surbhi Grover
Journal:  Laryngoscope       Date:  2020-10-24       Impact factor: 3.325

9.  Favorable Lip and Oral Cancer Mortality-to-Incidence Ratios in Countries with High Human Development Index and Expenditures on Health.

Authors:  Wen-Wei Sung; Yong-Chen Hsu; Chen Dong; Ying-Ching Chen; Yu-Chi Chao; Chih-Jung Chen
Journal:  Int J Environ Res Public Health       Date:  2021-06-03       Impact factor: 3.390

10.  Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.

Authors:  Bin Yang; Li Zhou; Jing Zhong; Tangfeng Lv; Ang Li; Lu Ma; Jian Zhong; Saisai Yin; Litang Huang; Changsheng Zhou; Xinyu Li; Ying Qian Ge; Xinwei Tao; Longjiang Zhang; Yong Son; Guangming Lu
Journal:  Respir Res       Date:  2021-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.